From Lab Bench to Market Shelf: The Hidden Gauntlet Facing CRISPR Commercialization

When the FDA approved Casgevy—the first CRISPR-based therapy—in late 2023, the scientific community celebrated what appeared to be a watershed moment. And in many respects, it was. But behind that milestone lay years of capital-intensive development, manufacturing setbacks, and regulatory negotiations that nearly derailed the program multiple times. Casgevy's approval was not a sign that the commercialization problem had been solved. It was a reminder of just how formidable that problem remains.

For every CRISPR venture that reaches the clinic, dozens more stall in the transition between proof-of-concept and a product that can be manufactured consistently, priced accessibly, and administered safely at scale. Understanding why requires looking beyond the science itself and into the structural realities of bringing a gene-editing therapy to market in the United States.

The Manufacturing Wall

The most immediate obstacle most CRISPR companies encounter is not biological—it is logistical. Producing a gene-editing therapy at clinical scale is a fundamentally different challenge from generating the quantities needed for early laboratory experiments.

For autologous cell therapies, in which a patient's own cells are extracted, edited, and reinfused, the manufacturing process must be individualized for each patient. That means no economies of scale in the traditional pharmaceutical sense. Each batch requires its own quality controls, its own documentation trail, and its own cold-chain logistics. The result is a cost structure that can push per-patient treatment expenses into the millions of dollars—a price point that creates immediate access and reimbursement complications before a single commercial sale is made.

Allogeneic approaches, which use donor-derived cells that can theoretically be manufactured in larger batches, offer a potential workaround. But these come with their own scientific and regulatory complexities, including managing immune rejection risks and ensuring consistent editing outcomes across diverse patient populations. Neither model has yet demonstrated a clear path to the kind of cost reduction that would make CRISPR therapies broadly accessible.

Beyond cell therapies, in vivo delivery—where editing machinery is administered directly to a patient—presents a separate manufacturing challenge. Lipid nanoparticles and viral vectors capable of delivering CRISPR components to specific tissues must be produced under stringent Good Manufacturing Practice conditions. Viral vector manufacturing capacity in the United States remains constrained, and competition for that capacity among gene therapy developers of all kinds has driven lead times and costs sharply upward.

Regulatory Complexity as a Capital Drain

The FDA has made meaningful strides in developing frameworks for gene therapy review, including the establishment of dedicated guidance documents and accelerated pathways for conditions with unmet medical need. Nevertheless, the regulatory process for CRISPR-based therapies remains one of the most resource-intensive in the pharmaceutical landscape.

Because CRISPR represents a genuinely novel modality—one that permanently alters the genome—regulators require extensive long-term safety data that simply cannot be generated quickly. Off-target editing effects, in particular, demand rigorous characterization. Demonstrating that an editing event is both precise and durable across a patient population takes time measured in years, not months.

For smaller biotech companies without the balance sheets of large pharmaceutical partners, the cost of generating this data can be prohibitive. A single Phase 1 safety trial for a CRISPR therapy can run well into nine figures when manufacturing, clinical site management, and regulatory affairs expenses are fully accounted for. Companies that enter this process undercapitalized often find themselves forced to raise additional funds at disadvantageous terms—or to seek partnership agreements that significantly dilute their long-term upside.

The regulatory uncertainty surrounding novel delivery mechanisms compounds the problem. When a company pioneers a new approach to in vivo delivery, it frequently encounters questions from reviewers that no established precedent can answer, triggering requests for additional studies that extend timelines and consume resources.

The Funding Gap Between Promise and Product

Venture capital flowed into CRISPR companies at remarkable rates during the early 2020s, fueled by the excitement surrounding early clinical data and the Nobel Prize recognition that CRISPR received in 2020. But funding sentiment has shifted considerably since then. Investors who entered the sector expecting near-term returns have grown impatient with the long development timelines that gene therapy requires, and the capital markets that once welcomed CRISPR IPOs with enthusiasm have become considerably more selective.

The result is a pronounced funding gap at a critical developmental stage. Early discovery work is relatively inexpensive and attracts academic and seed-stage support. Late-stage clinical trials, if a company survives long enough to reach them, can attract large pharmaceutical partnership interest. But the middle stage—where manufacturing processes must be developed and validated, where IND-enabling studies must be conducted, where regulatory strategy must be built out in detail—is frequently underserved by both early-stage and late-stage capital sources.

Some companies are addressing this gap through creative deal structures. Licensing arrangements that front-load milestone payments, non-dilutive funding from patient advocacy foundations, and government grants from agencies such as BARDA and the NIH's National Center for Advancing Translational Sciences have all become important components of CRISPR financing strategies. A number of companies have also pursued platform licensing models, generating near-term revenue by licensing their editing tools to agricultural, industrial, or diagnostics applications while continuing to fund therapeutic development.

Companies Rewriting the Playbook

Among the ventures making notable progress against these structural headwinds, a common thread is a willingness to challenge inherited assumptions about how gene therapies should be built and delivered.

Several emerging companies have focused intensively on reducing manufacturing complexity through automation and closed-system bioprocessing, compressing the cost and time required to produce individualized therapies. Others have invested in building proprietary delivery platforms designed specifically to reduce dependence on viral vectors, which remain a persistent bottleneck. A smaller cohort has taken a deliberately disease-agnostic approach, developing manufacturing and regulatory infrastructure that can be applied across multiple indications rather than optimizing for a single target.

What these approaches share is a recognition that scientific innovation alone is insufficient. The companies most likely to move CRISPR from clinical curiosity to commercial reality are those treating the manufacturing, regulatory, and financial dimensions of the problem with the same rigor they apply to the biology.

The Stakes for American Biotech Leadership

The United States has a substantial strategic interest in ensuring that CRISPR commercialization succeeds on domestic soil. International competitors—particularly in China and parts of Europe—are investing heavily in gene therapy infrastructure, and the window for American companies to establish durable market leadership is not indefinite.

Addressing the commercialization gap will require coordinated effort. Regulatory agencies can accelerate progress by building institutional expertise in novel modalities and providing clearer early guidance to developers. Capital markets can play a constructive role by developing investment structures better suited to the long development horizons that gene therapy demands. And research institutions can contribute by prioritizing translational training that prepares scientists to navigate the commercial realities their discoveries will eventually encounter.

The science of gene editing has already proven itself. The work that remains is the harder, less glamorous work of building the systems that can deliver it.